Objective: The correlation of HbA1c level with mortality in patients with ischemic stroke and Paroxysmal Atrial Fibrillation (pAfib).
Method: 278 patients with medical history of ischemic stroke and pAfib confirmed with cerebral Computed Tomography and electrocardiogram or rhythm Holter respectively, were included in the study. All patients visited for routine health screening examination or with minor deseases the departments of internal medicine of three tertiary hospitals. The mean age was 78±12 years. The participants were divited into two groups: In group A, 167 patients (60%) that had diabetes mellitus type II (DMT2) were included. Among them, 92 were women (55%) and 75 were men (45%). The remaining 111 patients (58 women (52%) and 53 men (48%)) had no medical history of DMT2, and were included in group B. Among others, HbA1c was measured in all patients in months 6,12,18,24,36 and a survival/ events follow-up was recorded. The study duration was 36 months.
Results: In group A, 20 deaths of patients (12%) were reported, among them 8 were men (40%) and 12 were women (60%) with average HbA1c measurements during the follow-up period: 2 patients (10%) with 6,5<HbA1c<7, 6 patients (30%) with 7<HbA1c<8,5 and 12 patients (60%) with HbA1c>8,5. In group B, 10 deaths (9%) were reported. Among them, 4 men (40%) and 5 women (60%) with measurement 6<HbA1c<6,5 and 1 woman (10%) with HbA1c<6. The mortality for patients with ischemic stroke and pAfib is increased with the increase of HbA1c in patients with DMT2 in a statistically significant manner (p 0.0031). An non-statistically significant increase in mortality was also observed in group B. (p 0.22).
Conclusion: The increase in the level of HbA1c increases the mortality in patients with ischemic stroke and pAfib especially in those with DMT2.
Disclosure
K. Kanellopoulou: None. I.L. Matsoukis: None. A. Ganotopoulou: None. T. Athanasopoulou: None. C. Triantafillopoulou: None. A. Sianni: None.
Introduction: GLP-1 analogues and SGLT2 inhibitors have complementary mechanisms of action. The aim of the study is to evaluate the results and tolerance of the combination of these medicines.
Purpose: To investigate the effect of the combination of GLP-1 analogues and SGLT2 inhibitors on obese patients with non-insulin-treated DM2.
Method: The study included 150 patients, out of which 110 (73.3%) were women with a mean age of 58 ± 5 years and 40 (26.6%) were men with a mean age of 62 ± 6 years, The mean BMI was 36± 4 and all patients received oral medication for the treatment of DM2 (metformin ± DPP-4 ± sulfonylureas ± glitazone). The study duration was one year and HbA1c, fasting glucose, body weight, and body mass index (BMI) were measured at 3, 6, 9 and 12 months. All patients changed their medication to metformin + GLP-1 + SGLT2.
Results: A decrease in HbA1c levels were observed at 3 months (mean HbA1c 10 ± 1.8), at 6 months (mean HbA1c 9 ± 1.3), at 9 months (mean HbA1c 8.7 ± 1) and at 12 months (mean HbA1c 7 ± 0.8) (p = 0.030). Fasting glucose also showed a gradual reduction in the follow-up tests, namely 185 ± 29mg / dl, 168 ± 22mg / dl, 156 ± 20mg / dl and 145 ± 18mg / dl at 3, 6, 9 and 12 months respectively (p = 0.0045). Same results were also observed when body weight was measured at 3,6,9 and 12 months (125 ± 18 kg, 1± 14 kg, 100 ± 8 kg and 98 ± 8 kg respectively) (p = 0,042). Changes in BMI were also occured with a mean BMI of 42 ± 7.2 at 3 months, 40 ± 6.8 at 6 months, 38 ± 6.4 at 9 months and 35 ± 5 at 12 months of follow-up period (p = 0.043).
Conclusion: The combination of metformin + GLP-1 + SGLT2 has many benefits in the metabolic profile of obese patients with DM2 and could be considered as a choice treatment.
Disclosure
I.L. Matsoukis: None. A. Ganotopoulou: None. C. Triantafillopoulou: None. K. Kanellopoulou: None. T. Athanasopoulou: None. A. Sianni: None.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.